GoodRx cuts talk on $520 million term loan to Libor plus 300-325 bps

By Sara Rosenberg

New York, Oct. 3 – GoodRx reduced price talk on its $520 million seven-year first-lien term loan (B1/B+) to a range of Libor plus 300 basis points to 325 bps from a range of Libor plus 350 bps to 375 bps, according to a market source.

Also, the original issue discount on the first-lien term loan was revised to 99.75 from 99.5, the source said.

The first-lien term loan still has a 0% Libor floor and 101 soft call protection for six months.

The company’s $785 million of credit facilities also include a $40 million revolver (B1/B+) and a $225 million privately placed second-lien term loan.

Goldman Sachs Bank USA, Barclays, Bank of America Merrill Lynch, Credit Suisse Securities (USA) LLC, KKR Capital Markets, Citizens and SunTrust Robinson Humphrey Inc. are the leads on the deal.

Commitments continued to be due at 5 p.m. ET on Wednesday, the source added.

Proceeds will be used to help fund the acquisition of a significant minority stake in the company by Silver Lake Partners from existing owners Francisco Partners, Spectrum Equity and management.

GoodRx is a Santa Monica, Calif.-based operator of a prescription drug price comparison and coupon platform.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.